The role of multistraine probiotics in non-specific seasonal prevention of acute respiratory infections in children with recurrent URTI in organized teams

Introduction. A broad evidence base of numerous randomized clinical trials and meta-analyses asserts the role of intestinal microbiota dysbiosis in the development of various diseases, including those of infectious origin, in infancy and later stages of life.

Purpose. Assessment of the efficacy of a multi-strain immuno-probiotic during rehabilitation of frequently ill children visiting organized groups during the period of epidemiological distress for acute respiratory diseases.

Materials and methods.93 children older than 3 years of age were enrolled in an open comparative prospective clinical observation during the high-risk respiratory infection period  – November, December. Children were observed for 1.5 months during administration of the multi-strain probiotic and 1 month after discontinuation of the probiotic. The subjects were randomized into two groups: the treatment group (60 children) received the multi-strain probiotic in the maximum age-specific dosage variances (children aged 3 to 12 years old – 1 capsule, older than 12 years of age – 2 capsules) once a day in the morning for 14 days and the comparison group (33 children) did not receive the multi-probiotic for the same period.

Results and discussion. It was found that the incidence of disease in children receiving the multi-probiotic (the treatment group – 60 children) was statistically lower, and the disease severity was milder than in the group of children, who did not receive the probiotic (the comparison group – 33 children). Not a single child who received the multi-probiotic in the course of disease did not require antibiotic therapy during the entire observation period. Moreover, the incidence of respiratory infections in the treatment group within a month after discontinuation of the probiotic was 4.6 times lower than in the comparison group. No side effects were reported.

Conclusions. The study results allowed the author to recommend the use of a multi-strain immuno-probiotic as a nonspecific immunomodulatory supplement for the seasonal prevention of acute respiratory infections, especially in frequently ill children at a high risk of infections.

1. Parfrey L.W., Knight R. Spatial and temporal variability of the human microbiota. Clin Microbiol Infect. 2012;18(4 Suppl.):8–14. doi: 10.1111/j.1469-0691.2012.03861.x.

2. Oozer R., Rescigno M., Ross R.P., Knol J., Blaut M., Khlebnikov A., Doré J. Gut health: predictive biomarkers for preventive medicine and development of functional foods. Br J Nutr. 2010;103(10):1539–1544. doi: 10.1017/S0007114509993400.

3. Lee K.N., Lee O.Y. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol. 2014;20(27):8886–8897. doi: 10.3748/wjg.v20.i27.8886.

4. Matamoros S., Gras-Leguen C., Vacon F., Potel G., de La Cochetiere M.F. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol. 2013;21(4):167–173. doi: 10.1016/j.tim.2012.12.001.

5. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B. et al. Expert consensus document: The International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi: 10.1038/nrgastro.2014.66.

6. Zakharova I.N. Child intestinal microbiota and health: is there a link? Meditsinskiy sovet = Medical Council. 2015;(6):47–51. (In Russ.) doi: 10.21518/2079-701X-2015-6-47-51.

7. Gerritsen J., Smidt H., Rijkers G.T., de Vos W.M. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011;6:209–240. doi: 10.1007/s12263-011-0229-7.

8. Bertelsen R.J., Brantsæter A.L., Magnus M.C., Haugen M., Myhre R., Jacobsson B. et al. Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases. J Allergy Clin Immunol. 2014;133(1):165–171. doi: 10.1016/j.jaci.2013.07.032.

9. Munyaka P., Khafipour E., Ghia J.E. External influence of early childhood establishment of gut microbiota and subsequent health implication. Frontiers in Pediatrics. 2014;2:109. doi: 10.3389/fped.2014.00109.

10. Ussar S., Griffin N.V., Bezy O., Fujisaka S., Vienberg S.,Softic S. et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell Metab. 2015;22(3):516–530. doi: 10.1016/j.cmet.2015.07.007.

11. Luoto R., Kalliomaki M., Laitinen K., Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: followup study from birth to 10 years. Int J Obes. (Lond). 2010;34(10):1531–1537. doi: 10.1038/ijo.2010.50.

12. Engelbrektson A., Korzenik J.R., Pittler A., Sanders M.E., Klaenhammer T.R., Leyer G., Kitts C.L.Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol. 2016;58(5):663–670. doi: 10.1099/jmm.0.47615-0.

13. Rijkers G.T., Bengmark S., Enck P., Haller D., Herz U., Kalliomaki M. et al. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr. 2010;140(3):671–676. doi: 10.3945/jn.109.113779.

14. Szajewska H. Advances and limitations of evidence-based medicine–impact for probiotics. Ann Nutr Metab. 2010;57:6–9. doi: 10.1159/000309015.

15. Guarner F., Khan A.G., Garisch J., Eliakim R., Gangl A., Thomson A. et al. World Gastroenterology Organization. Global Guidelines: probiotics and prebiotics. October. 2011. J Clin Gastroenterol. 2012;46(6):468–481.doi: 10.1097/MCG.0b013e3182549092.

16. Ouwehand A.C., DongLian C., Weijian X., Stewart M., Ni J., Stewart T., Miller L.E. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458–463. doi: 10.1016/j.vaccine.2013.11.053.

17. Ringgel-Kulra T., Goldsmith J.R., Carroli I.M., Barros P., Palsson O., Jobin C., Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patient with functional abdominal pain – a rando mized clinical study. Aliment Pharmacol Ther.2014;40(2):200–207. doi: 10.1111/apt.12800.

18. Kalyuzhin O.V. Рrobiotic strains of lactobacilli as immunomodulators: focus on Lactobacillus rhamnosus GG. Meditsinskiy sovet = Medical Council. 2017;(9):108–115. (In Russ.) doi: 10.21518/2079-701X-2017-9-108-115.

19. Sugyan N.G., Zakharova I.N. BAC-SET multiprobiotic: results of russian and foreign clinical research. Meditsinskiy sovet = Medical Council. 2017;(19):104–110. (In Russ.) doi: 10.21518/2079-701X-2017-19-104-110.

20. Beausoleil M., Fortier N., Guénette S., L’Ecuyer A., Savoie M., Franco M., Weiss K. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-association diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol. 2007;21(11):732–736. doi: 10.1155/2007/720205.

21. West N.P., Hom P.L., Pyne D.B., Gebski V.J., Lahtinen S.J., Fricker P.A., Cripps A.W. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33(4):581–587. doi: 10.1016/j.clnu.2013.10.002.

22. Kalyuzhin O.V., Afanasyev S.S., Bykov A.S. Oral probiotics as anti-infectious immune response stimulators in the respiratory tract. Terapevticheskiy arkhiv = Therapeutic archive. 2016;88(5):118–124. (In Russ.) doi: 10.17116/terarkh2016885118-124.

23. Brenner D.M. Bifidobacterium infantis: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord. 2009;104(4):1033–1049. Available at: https://pubmed.ncbi.nlm.nih.gov/19367213/.

24. Purchiaroni F., Tortora A., Gabrielli M., Bertucci F., Gigante G., Ianiro G. et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17(3):323–333. Available at: https://pubmed.ncbi.nlm.nih.gov/23426535.

25. Chaplin A.V., Brzhozovskii A.G., Parfenova T.V., Kafarskaia L.I., Volodin N.N., Shkoporov A.N. et al. Species Diversity of Bifidobacteria in the Intestinal Microbiota Studied Using MALDI-TOF Mass-Spectrometry. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2015;70(4):435–440. (In Russ.) doi: 10.15690/vramn.v70.i4.1409.

26. Ho J.T., Chan G.C., Li J.C. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol. 2015;16:21. doi: 10.1186/s12865-015-0083-2.

27. National Research Council (US) Committee on New Directions in the Study of Antimicrobial Therapeutics: New Classes of Antimicrobials; National Research Council (US) Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation. Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics. Washington (DC): National Academies Press (US); 2006. doi: 10.17226/11471.

28. Floch M.H., Walker W.A., Madsen K., Sanders M.E., Macfarlane G.T., Flint H.J. et al. Recommendations for probiotic use-2011update. J Clin Gastroenterol. 2011;45:168–171. doi: 10.1097/MCG.0b013e318230928b.

29. Foster L.M., Tompkins T.A., Dahl W.J. A comprehensive post-market review of studies on a probiotic containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. Beneficial Microbes.2011;2(4):319–334. doi: 10.3920/BM2011.0032.

30. Gorelov A.V., Ploskireva A.A., Bondareva A.V., Kanner E.V. Probiotics in complex prevention of respiratory infections. Voprosy prakticheskoy pediatrii = Clinical Practice in Pediatrics. 2014;9(5):77–83. (In Russ.) Available at: https://medi.ru/info/12831.

31. King S., Glanville J., Sanders M.E., Fitzgerald A., Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr. 2014;112(1):41–54. doi: 10.1017/S0007114514000075.

32. Pregliasco F., Anselmi G., Fonte L., Giussani F., Schieppati S., Soletti L.A new chance of preventing winter diseases by the administration of synbiotic formulations. J Clin Gastroenterol. 2008;42(3 Suppl.):224–233.doi: 10.1097/MCG.0b013e31817e1c91.

33. Ichinohe Т., Pang I.K., Kumamoto Y., Kumamoto Y., Peaper D.R., Ho J.H. et al. Microbiota regulatesimmune defense against respiratory tract influenza A virus infection. Proc Nat Acad Sci USA. 2011;108(13):5354–5359.doi: 10.1073/pnas.1019378108.

34. Yala E.T. The Clinical Efficacy of Multi-strain Probiotics (Bac-Set) in the Management of Acute Gastroenteritis in Children Two Months to Two Years Old. PIDSP Journal. 2010;11(2):86–91. Available at: http://pidsphil.org/pdf/Journal_12312011/jo39_ja05.pdf.

35. Martynova G.P., Solovyova I.A., Menschikova M.L., Erohina E.S., Belkina A.B., Bezrukih N.A. Probiotic correction in complex treatment of rotavirus infection in children in the first years. Prakticheskaya meditsina = Practical Medicine. 2016;(8):143–147. (In Russ.) Available at: http://pmarchive.ru/probio ticheskaya-korrekci-ya-v-kompleksnom-lechenii-rotavirusnojinfekcii-u-detej-pervyx-let-zhizni.

36. Kharitonova L.A., Kucherya T.V. Using Probiotics in Pediatric Practice: Clinical Study Results. Doctor.Ru.2016;6(123):38–41. (In Russ.) Available at: https://journaldoctor.ru/catalog/pediatriya/primenenie-probiotika-v-pediatricheskoypraktike-rezultaty-klinicheskogo-issledovaniya/?lang=ru&clear_cache=Y.

37. Revyakina V.A., Larkova I.A., Mukhortykh V.A. Efficacy of probiotic use in children with gastrointestinal food allergies. Voprosy detskoy dietologii = Pediatric Nutrition. 2017;15(1):57–58. (In Russ.)

38. Ishaque M., Khosruzzaman S., Ahmed D., Sah M. A randomized placebocontrolled clinical trial of a multi-strain probiotic formulation (BioKult®) in the management of diarrheapredominant irritable bowel syndrome. Meditsinskiy sovet = Medical Council. 2018;(14):98–108. (In Russ.) doi: 10.21518/2079-701X-2018-14-98-108.

39. Rhedin S., Lindstrand A., Rotzén-Östlund M., Tolfvenstam T., Ohrmalm L., Rinder M.R. et al. Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics. 2014;133(3):538–545. doi: 10.1542/peds.2013-3042.

40. Samsygina G.A., Koval G.S. Frequently ill children, the problem of diagnosis, pathogenesis and therapy. Lechaschi Vrach Journal. 2009;(1):10–15. (In Russ.) Available at: https://lvrach.ru/2009/01/5897153.

41. Namazova L., Botvin’eva V., Voznesenskaya N. Modern means of immune theraphy for sickly children with allergic diseases. Pediatricheskaya farmakologiya = Pediatric Pharmacology. 2007;4(1):27–32. (In Russ.) Available at: https://pedpharma.ru/jour/article/view/622.

42. Nazzari E., Torretta S., Pignataro L., Marchisio P., Esposito S. Role of biofilm in children with recurrent upper respiratory tract infections. Eur J Clin Microbiol Infect Dis. 2015;34(3):421–429. doi: 10.1007/s10096-014-2261-1.

43. Ursova N.I. Immunological function of intestinal microflora, its abnormalities and possibilities of correction. Almanakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2015;(40):35–46. (In Russ.) doi: 10.18786/2072-0505-2015-40-35-46.

44. Karaulov A.V. Immunity dysfunction in respiratory diseases: do frequently ill children need immunomodulators? Voprosy sovremennoy pediatrii =Current Pediatrics. 2015;14(2):260–264. (In Russ.) doi: 10.15690/vsp.v14i2.1295.

45. Khavkin A.I.Impact of prebiotics on immune system. Effektivnaya farmakoterapiya. Pediatriya = Effective Pharmacotherapy. Pediatrics. 2014;(4):34–40. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22635401.

46. Cong Y., Feng T., Fujihashi K., Schoeb T.R., Elson C.O. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A. 2009;106(46):19256–19261. doi: 10.1073/pnas.0812681106.